(Circulation. 1998;98:1993-1999.)
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports |
Associations Between Lipoproteins and the Progression of Coronary and Vein-Graft Atherosclerosis in a Controlled Trial With Gemfibrozil in Men With Low Baseline Levels of HDL Cholesterol
From the Department of Medicine, Helsinki University Central Hospital (M.S., M.S.N., M.H.F., M-R.T.); the Department of Medicine and Biocenter Oulu, Oulu University Hospital and University of Oulu (H.K., Y.A.K.); the Department of Medicine, Tampere University Hospital (S.M., V.V., A.P.); and the Department of Biochemistry, National Public Health Institute, Helsinki (C.E.), Finland.
Background—Lipid-lowering secondary-prevention trials of coronary artery disease (CAD) have implicated triglyceride-rich lipoproteins as the main determinants of angiographic progression after elevated LDL cholesterol levels have been lowered with therapy. The present study focuses on the lipoprotein determinants of angiographic CAD progression in men with low HDL cholesterol concentration as their main baseline lipid abnormality who underwent 32 months of randomized therapy with gemfibrozil or placebo.
Methods and Results—Men who had undergone coronary bypass surgery (n=372) completed a randomized, placebo-controlled study with gemfibrozil 1200 mg/d. They were selected primarily for HDL cholesterol levels that corresponded to the lowest third for middle-aged men. Average baseline lipid and lipoprotein levels were serum triglyceride, 1.60; serum cholesterol, 5.17; ultracentrifugally separated LDL cholesterol, 3.43; HDL2 cholesterol, 0.41; and HDL3 cholesterol, 0.61 mmol/L. In the gemfibrozil group, these levels were reduced on average by 40%, 9%, and 6% or increased by 5% and 9%, respectively. On-trial IDL and LDL triglyceride and cholesterol levels significantly predicted global angiographic progression, taking into account changes in native segments and in bypass grafts. HDL3 but not HDL2 cholesterol concentration was associated with protection against progression, especially focal disease in native coronary lesions. VLDL was the lipoprotein most predictive of new lesions in vein grafts; IDL was also significantly related.
Conclusions—This study expands the previous evidence of the triglyceride-rich lipoproteins, especially IDL, as predictors of angiographic progression of CAD but does not negate the significance of mildly elevated LDL levels. Of the HDL subfractions, only HDL3 was protective in this group of men selected for their low initial HDL levels.
Key Words: coronary disease • bypass • lipoproteins • angiography • trials
This article has been cited by other articles:
 |
|
 |
|
  K. El Harchaoui, B. J. Arsenault, R. Franssen, J.-P. Despres, G. K. Hovingh, E. S.G. Stroes, J. D. Otvos, N. J. Wareham, J. J.P. Kastelein, K.-T. Khaw, et al. High-Density Lipoprotein Particle Size and Concentration and Coronary Risk Ann Intern Med, January 20, 2009; 150(2): 84 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Otvos, D. Collins, D. S. Freedman, I. Shalaurova, E. J. Schaefer, J. R. McNamara, H. E. Bloomfield, and S. J. Robins Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial Circulation, March 28, 2006; 113(12): 1556 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Barish Peroxisome Proliferator-Activated Receptors and Liver X Receptors in Atherosclerosis and Immunity J. Nutr., March 1, 2006; 136(3): 690 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Talmud, S. Martin, M.-R. Taskinen, M. H. Frick, M. S. Nieminen, Y. A. Kesaniemi, A. Pasternack, S. E. Humphries, and M. Syvanne APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study J. Lipid Res., April 1, 2004; 45(4): 750 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Duez, Y.-S. Chao, M. Hernandez, G. Torpier, P. Poulain, S. Mundt, Z. Mallat, E. Teissier, C. A. Burton, A. Tedgui, et al. Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor alpha Agonist Fenofibrate in Mice J. Biol. Chem., December 6, 2002; 277(50): 48051 - 48057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Herrington, T. D. Howard, G. A. Hawkins, D. M. Reboussin, J. Xu, S. L. Zheng, K. B. Brosnihan, D. A. Meyers, and E. R. Bleecker Estrogen-Receptor Polymorphisms and Effects of Estrogen Replacement on High-Density Lipoprotein Cholesterol in Women with Coronary Disease N. Engl. J. Med., March 28, 2002; 346(13): 967 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Kreisberg and A. Oberman Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 423 - 437. [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Robins, D. Collins, J. T. Wittes, V. Papademetriou, P. C. Deedwania, E. J. Schaefer, J. R. McNamara, M. L. Kashyap, J. M. Hershman, L. F. Wexler, et al. Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events: VA-HIT: A Randomized Controlled Trial JAMA, March 28, 2001; 285(12): 1585 - 1591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Oberman Hypertriglyceridemia and Coronary Heart Disease J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2098 - 2105. [Full Text]
|
|
|
|
|
|
D. M. Flavell, Y. Jamshidi, E. Hawe, I. Pineda Torra, M.-R. Taskinen, M. H. Frick, M. S. Nieminen, Y. A. Kesaniemi, A. Pasternack, B. Staels, et al. Peroxisome Proliferator-Activated Receptor {alpha} Gene Variants Influence Progression of Coronary Atherosclerosis and Risk of Coronary Artery Disease Circulation, March 26, 2002; 105(12): 1440 - 1445. [Abstract] [Full Text] [PDF]
|
|